Introducing Medisca Nutraceuticals

Download in electronic PDF format for $25



Search the Complete Journal Archives

Compatibility of Docetaxel with Selected Drugs during Simulated Y-Site Administration

Author(s):  Trissel Lawrence A, Gilbert Doward L, Wolkin Allan C

Issue:  May/Jun 1999 - Compounding for Animals
View All Articles in Issue

Abstract:  The compatibility of docetaxel with 81 secondary additives during simulated Y-site injection was evaluated by visual observation with the unaided eye and a Tyndall beam as well as with electronic turbidity measurement.

Five milliliters of docetaxel 0.9 mg/mL in 5% dextrose injection was combined with 5 mL of solutions of 81 secondary additives including supportive-care drugs and anti-infectives in 5% dextrose injection or, if necessary to avoid incompatibilities with the diluent, 0.9% sodium chloride injection. Visual examinations were performed in fluorescent light with the unaided eye and a Tyndall beam (high-intensity monodirectional light beam) to enhance visualization of small particles and low-level turbidity. The turbidity of each sample was quantitated as well. Evaluation of the samples was performed initially and at one and four hours after preparation.

Most of the drugs tested were physically compatible with docetaxel at 0.9 mg/mL. However, three drugs exhibited incompatibilities with docetaxel within the four-hour observation period. Amphotericin B resulted in the formation of a substantially more intense haze measuring about 11.5 nephelometric turbidity units (NTU) after four hours; the haze was visible in normal room light. The nalbuphine hydrochloride mixtures resulted in a small increase of about 0.8 NTU in subvisual haze. The methylprednisolone sodium succinate combination resulted in a small loss of the expected natural haze of about 0.5 to 0.6 NTU.

Docetaxel was physically compatible with 78 supportive care and anti-infective drugs during simulated simultaneous Y-site administration. However, amphotericin B, nalbuphine hydrochloride, and methylprednisolone sodium succinate resulted in physical incompatibilities. Simultaneous Y-site administration of these three drugs with docetaxel should be avoided.

Related Keywords: nalbuphine hydrochloride, methylprednisolone sodium succinate

Related Categories: CANCER AND AIDS, PEER-REVIEWED, STABILITIES, COMPATIBILITIES

Printer-Friendly Version

Related Articles from IJPC
Title (Click for Abstract / Details) Author Issue Page View/Buy
Physical and Chemical Stability of Palonosetron Hydrochloride with Dacarbazine and with Methylprednisolone Sodium Succinate During Simulated Y-Site Administration Trissel Lawrence A, Xu Quanyun A, Zhang Yanping May/Jun 2006 234-236 Buy
Chemical Stability of Methylprednisolone Sodium Succinate After Reconstitution in 0.9% Sodium Chloride Injection and Storage in Polypropylene Syringes Gupta Vishnu D Mar/Apr 2001 148-150 Buy
Nalbuphine Hydrochloride 10-mg/mL Injection Allen Loyd V Jr Sep/Oct 2012 426 Buy
Stability of Ampicillin Sodium, Nafcillin Sodium, and Oxacillin Sodium in AutoDose Infusion System Bags Zhang Yanping, Trissel Lawrence A May/Jun 2002 226-229 Buy
Compatibility of Docetaxel with Selected Drugs during Simulated Y-Site Administration Trissel Lawrence A, Gilbert Doward L, Wolkin Allan C May/Jun 1999 241-244 Buy
Palonosetron Hydrochloride Compatibility and Stability with Three Beta-Lactam Antibiotics During Simulated Y-Site Administration Ben Michel, Trusley Craig, Kupiec Thomas C, Trissel Lawrence A Nov/Dec 2007 520-524 Buy
Hydrocortisone 50-mg/mL Injection (as the Sodium Succinate) Allen Loyd V Jr Nov/Dec 2013 504 Buy
Cyclobenzaprine Hydrochloride 0.5% and Diclofenac Sodium 3% in Pluronic Lecithin Organogel Allen Loyd V Jr Nov/Dec 2008 540 Buy
Methylprednisolone 4-mg/mL Oral Suspension Allen Loyd V Jr Jul/Aug 2011 340 Buy
Methylprednisolone 40-mg/mL Injection Allen Loyd V Jr Mar/Apr 2014 145 Buy